Previous close | 2.8900 |
Open | 3.2000 |
Bid | 2.6300 |
Ask | 3.3000 |
Strike | 40.00 |
Expiry date | 2025-08-15 |
Day's range | 2.8900 - 3.4300 |
Contract range | N/A |
Volume | |
Open interest | 464 |
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
GameStop shares continue their surge in May, a report says Arm Holdings seeks to launch its first artificial-intelligence chips next year, and Squarespace is being taken private in a deal valued at $6.9 billion.
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.